Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fennec Pharmaceuticals Inc (FRX.TO)

Fennec Pharmaceuticals Inc (FRX.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 362,027
  • Shares Outstanding, K 34,153
  • Annual Sales, $ 47,538 K
  • Annual Income, $ -436 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 2.51
  • Price/Sales 5.46
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.00
  • Number of Estimates 2
  • High Estimate 0.00
  • Low Estimate -0.01
  • Prior Year -0.08
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.51 +0.86%
on 12/03/25
12.50 -15.20%
on 11/18/25
-1.10 (-9.40%)
since 11/05/25
3-Month
10.51 +0.86%
on 12/03/25
13.83 -23.36%
on 10/07/25
-1.59 (-13.04%)
since 09/08/25
52-Week
7.02 +51.00%
on 04/08/25
13.83 -23.36%
on 10/07/25
+2.03 (+23.69%)
since 12/09/24

Most Recent Stories

More News
Stocks in play: Fennec Pharmaceuticals Inc.

Today announced the planned initiation of an investigator-sponsored study (IST) by City of Hope, a U.S. ...

FRX.TO : 10.60 (+0.57%)
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

– City of Hope to Evaluate PEDMARK ® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors – – Initiation of Study Reflects Growing Clinical Interest...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Stocks in play: Fennec Pharmaceuticals Inc.

Today announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical ...

FRX.TO : 10.60 (+0.57%)
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Stocks in play: Fennec Pharmaceuticals Inc.

Announced it has repurchased and redeemed all of Fennec’s outstanding convertible notes issued to Petrichor ...

FRX.TO : 10.60 (+0.57%)
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption

RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada

RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares

RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 10.60 (+0.57%)
FENC : 7.55 (+0.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

See More

Key Turning Points

3rd Resistance Point 10.60
2nd Resistance Point 10.60
1st Resistance Point 10.60
Last Price 10.60
1st Support Level 10.60
2nd Support Level 10.60
3rd Support Level 10.60

See More

52-Week High 13.83
Fibonacci 61.8% 11.23
Last Price 10.60
Fibonacci 50% 10.43
Fibonacci 38.2% 9.62
52-Week Low 7.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar